Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boryung Cell-culture Japanese Encephalitis Vaccine is an inactivated, Vero cell-derived vaccine developed by Boryung Biopharma for active immunization against Japanese encephalitis (JE). It is produced by cultivating the Beijing-1 strain of the Japanese encephalitis virus in Vero cells, followed by purification and inactivation with formaldehyde. This cell-culture method is designed to reduce the risk of adverse reactions associated with older mouse brain-derived vaccines. The vaccine is approved in South Korea for pediatric and adult populations and is administered via subcutaneous injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on japanese encephalitis vaccine (Boryung).